Wave life sciences announces pricing of $70.0 million underwritten offering

Cambridge, mass., june 14, 2022 (globe newswire) -- wave life sciences ltd. (nasdaq: wve), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of an underwritten offering (the “offering”) of 25,464,483 of its ordinary shares at an offering price of $2.15 per ordinary share, and, to ra capital management, l.p. in lieu of ordinary shares, pre-funded warrants to purchase up to 7,093,656 ordinary shares at an offering price of $2.1499 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant.
WVE Ratings Summary
WVE Quant Ranking